Patent · US Active

Opioid formulations

US9937164B2 · kind B2 · utility

5Cited by
24References
28Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 26, 2013
Grant dateApr 10, 2018
Priority date
Expiry dateJul 26, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P29/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.